GlassScriptPhysician profile
Magdalene Miller
NPI 1598237224
$391.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $84.26 | 2021-2022 | |
| Covis Pharma Gmbh | $64.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.28 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.73 | 2022 | |
| Pfizer INC. | $27.53 | 2021 | |
| Glaxosmithkline, LLC. | $26.44 | 2021 | |
| Csl Behring | $20.56 | 2021 | |
| Alk-Abello, INC | $15.69 | 2022 | |
| Genzyme Corporation | $14.91 | 2022 | |
| Uswm, LLC | $14.26 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.97 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.76 | 2021 | |
| Bio Products Laboratory USA, INC. | $6.12 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdalene Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.